An EGS Monte Carlo model for Varian TrueBEAM treatment units: Commissioning and experimental validation of source parameters.

In this work we have created and commissioned a Monte Carlo model of 6FFF Varian TrueBeam linear accelerator using BEAMnrc. For this purpose we have experimentally measured the focal spot size and shape of three Varian TrueBeam treatment units in 6FFF modality with a slit collimator and several depth dose and lateral beam profiles in a water phantom. The Monte Carlo model of a 6FFF TrueBeam machine was implemented with a primary electron source commissioned as a 2D Gaussian with Full Width Half Maximum selected by comparison of simulated and measured narrow beam profiles. The energy of the primary electron beam was optimized through a simultaneous fit to the measured beam depth dose profiles. Special attention was paid to evaluation of uncertainties of the selected Monte Carlo source parameters. These uncertainties were calculated by analysing the sensitivity of the commissioning process to changes in both primary beam size and energy. Both experimental and Monte Carlo commissioned focus size values were compared and found to be in excellent agreement. The commissioned Monte Carlo model reproduces within 1% accuracy the dose distributions of radiation field size from 3 cm × 3 cm to 15 cm × 15 cm.

Development and clinical characterization of a novel 2041 liquid-filled ionization chambers array for high-resolution verification of radiotherapy treatments.

PURPOSE: The aim of this study was to present a novel 2041 liquid-filled ionization chamber array for high-resolution verification of radiotherapy treatments. MATERIALS AND METHODS: The prototype has 2041 ionization chambers of 2.5 × 2.5 mm2 area filled with isooctane. The detection elements are arranged in a central square grid of 43 × 43, totally covering an area of 107.5 × 107.5 mm2 . The central inline and cross-line are extended to 227 mm and the diagonals to 321 mm to be able to perform profile measurements of large fields. We have studied stability, pixel response uniformity, dose rate dependence, depth and field size dependence and anisotropy. We present results for output factors, tongue-and-groove, garden fence, small field profiles, irregular fields, and verification of dose planes of patient treatments. RESULTS: Comparison with other detectors used for small field dosimetry (SFD, CC13, microDiamond) has shown good agreement. Output factors measured with the device for square fields ranging from 10 × 10 to 100 × 100 mm2 showed relative differences within 1%. The response of the detector shows a strong dependence on the angle of incident radiation that needs to be corrected for. On the other hand, inter-pixel relative response variations in the 0.95-1.08 range have been found and corrected for. The application of the device for the verification of dose planes of several treatments has shown gamma passing rates above 97% for tolerances of 2% and 2 mm. The verification of other clinical fields, like small fields and irregular fields used in the commissioning of the TPS, also showed large passing rates. The verification of garden fence and tongue-and-groove fields was affected by volume-averaging effects. CONCLUSIONS: The results show that the liquid filled ionization chamber prototype here presented is appropriate for the verification of radiotherapy treatments with high spatial resolution. Recombination effects do not affect very much the verification of relative dose distributions. However, verification of absolute dose distributions may require normalization to a radiation field which is representative of the dose rate of the treatment delivered.

Correction for FDG PET dose extravasations: Monte Carlo validation and quantitative evaluation of patient studies.

PURPOSE: Current procedure guidelines for whole body [18F]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) state that studies with visible dose extravasations should be rejected for quantification protocols. Our work is focused on the development and validation of methods for estimating extravasated doses in order to correct standard uptake value (SUV) values for this effect in clinical routine. METHODS: One thousand three hundred sixty-seven consecutive whole body FDG-PET studies were visually inspected looking for extravasation cases. Two methods for estimating the extravasated dose were proposed and validated in different scenarios using Monte Carlo simulations. All visible extravasations were retrospectively evaluated using a manual ROI based method. In addition, the 50 patients with higher extravasated doses were also evaluated using a threshold-based method. RESULTS: Simulation studies showed that the proposed methods for estimating extravasated doses allow us to compensate the impact of extravasations on SUV values with an error below 5%. The quantitative evaluation of patient studies revealed that paravenous injection is a relatively frequent effect (18%) with a small fraction of patients presenting considerable extravasations ranging from 1% to a maximum of 22% of the injected dose. A criterion based on the extravasated volume and maximum concentration was established in order to identify this fraction of patients that might be corrected for paravenous injection effect. CONCLUSIONS: The authors propose the use of a manual ROI based method for estimating the effectively administered FDG dose and then correct SUV quantification in those patients fulfilling the proposed criterion.